Lei Kang

  • Tesla brings back turn signal stalk for Model 3 in China

    Tesla has reintroduced the turn signal stalk as standard on the Model 3 sedan in China and is offering it as a paid option for vehicles already delivered.

  • Huawei to launch new models under Luxeed and Aito brands on Aug 25

    The updated S7 sedan and R7 coupe SUV from Luxeed, as well as the BEV variant of Aito M8, will be launched at the event.

  • Leapmotor turns profitable in H1, raises 2025 sales target

    Leapmotor has become the second Chinese NEV maker to achieve profitability on a half-year basis. It has raised its 2025 sales target to 580,000–650,000 units.

  • Dongfeng M-Hero launches M817 off-road SUV equipped with Huawei technologies, starting at $44,540

    The M-Hero M817 is a five-seat off-road SUV with a maximum power output of 505 kW (687 horsepower).

  • Wuling launches updated Starlight S SUV with starting price of $13,900

    Wuling offers PEHV and BEV options for the updated Starlight S, with the BEV variant offering a range of up to 510 kilometers.

  • WeRide secures investment from Grab to expedite robotaxi deployment in Southeast Asia

    Grab will invest tens of millions of dollars in WeRide, with the transaction expected to close by the first half of 2026.

  • Hesai to supply LiDARs to Toyota's joint venture in China

    Hesai did not disclose the name of the Toyota joint venture, but said that the automaker's models equipped with its ATX LiDAR will go into mass production in 2026.

  • BYD brings Yuan Up compact SUV to Hong Kong

    The BYD Yuan Up, renamed Atto 2 in Hong Kong, starts at 155,000 Hong Kong dollars ($19,750).

  • Changan Deepal launches updated L07 sedan featuring Huawei's smart driving system

    The updated Deepal L07 is available in BEV and EREV variants, with a starting guide price of RMB 145,900 ($20,350).

  • China NEV retail at 262,000 in Aug 1-10, up 6% year-on-year

    From August 1 to 10, China's total passenger vehicle retail sales totaled 452,000 units, down 4 percent year-on-year.